Consumer-driven enforcement can supplement but not replace regulatory capacity. Examine in the context of medicine pricing in India.

From 9 November 2026, revised MRPs of anti-cancer drugs under a 30% trade margin cap (Para 19, DPCO 2013) depend partly on patients checking prices and reporting overcharging [1][2]. Such vigilance detects violations, but only a capable regulator can correct them.

How consumers supplement regulation

• Price visibility: the pack MRP, NPPA's Pharma Sahi Daam app and its website let buyers verify revised prices [1].
• Grievance route: the Pharma Jan Samadhan portal and NPPA helpline turn buyers into sources of overcharging leads [1].
• Blind-spot coverage: NPPA's private-agency data covers about 70% of the market and misses hospital sales and e-commerce supplies [3]; complaints can flag violations there.

Why consumers cannot replace regulatory capacity

• Unequal position: about 60% of households borrow for cancer hospitalisation, according to studies the government has cited [4]; patients in acute treatment can hardly act as enforcers.
• Silence is not compliance: NPPA reported no complaint from Maharashtra on loose medicines sold above per-unit MRP [6]; this shows only what was reported.
• Limits of knowledge: buyers can check an MRP, not judge it; non-scheduled formulations, 82% of the market, can launch at arbitrary prices [3].
• Recovery gap: ₹8,526 crore (85%) of overcharging demands stayed unrecovered in 2025, 70% of it under litigation [3]; a complaint cannot end a court case.
• Thin capacity: 15 of NPPA's 48 sanctioned posts are vacant [3]; State Drug Controllers enforce the cancer order [2], yet NPPA keeps no state-wise overcharging record [5].

Way forward

• Fill NPPA vacancies, create a dedicated legal cell and fast-track disputes, as Standing Committee Report No. 33 urged [3].
• Bring hospital sales into government price data [3], since hospitals answer for revised prices on direct supply [2].
• Publish state-wise cases and recoveries, so that weak enforcement becomes visible.

Thus, consumer vigilance widens detection, while data, inspection and adjudication secure compliance. Informed patients backed by a well-staffed NPPA and capable State Drug Controllers would make affordable medicine enforceable, advancing the right to health under Article 21 and SDG 3.8.